Published in Blood Weekly, October 23rd, 2003
Pursuant to the collaboration and license agreement dated July 8, 2002, Fujisawa has a right of termination that provides for a 60-day period for termination of the agreement following receipt of the executive summary of the MBI 226 phase III study results.
Prior to this extension, Fujisawa had until September 22, 2003, to make its decision. Fujisawa and Micrologix have agreed to extend this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.